Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700744 | 0.89 | PTGDR2 (0.33) | — | |
| SCHEMBL476415 | 0.89 | HTR6 (0.35) | NAMPTGRM5 | |
| SCHEMBL476339 | 0.88 | HTR6 (0.32) | NAMPT | |
| SCHEMBL476365 | 0.88 | APLNR (0.35) | NAMPTAPLNRGLO1SLC40A1CXCR3 | |
| SCHEMBL3705969 | 0.86 | SLC16A3 (0.39) | — | |
| SCHEMBL476326 | 0.86 | COMT (0.36) | KCNA5 | |
| SCHEMBL3698418 | 0.84 | PTGDR2 (0.32) | — | |
| SCHEMBL476394 | 0.83 | HTR2C (0.37) | NAMPTRORCAPLNR | |
| SCHEMBL3697999 | 0.83 | P2RX7 (0.33) | — | |
| SCHEMBL476373 | 0.81 | GLO1 (0.39) | NAMPTGRM5APLNRGLO1SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2412713-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095057-A1 | PYRAZOLE COMPOUND | CEL, HRH2, GIPR | NAMPT 2506/4885RORC 1348/4885GRM5 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.